Combo Therapy & Durable Responses in Urothelial Carcinoma

Role of FGFR3 in Urothelial Carcinoma

Background and Objective: This study was undertaken to analyze the immunohistochemical expression of fibroblast growth factor receptor (FGFR3) in urothelial carcinoma and correlate its expression with the pathological stage, recurrence and other clinicopathological parameters. Material and Methods: A retrospective study was undertaken on paraffin blocks o...

Therapy for Metastatic Urothelial Carcinoma

but little improvement has been achieved in the outcomes of patients with advanced or metastatic disease. Almost 90% of those patients eventually succumb to their cancer. For patients who relapse after first-line chemotherapy, the prognosis is generally poor. To date, there is no real consensus on how to best treat these patients, and most of the available evidence stems from small phase ii tri...

Trimodality therapy in variant urothelial carcinoma: choose wisely

Neo/Adjuvant Therapy in Upper Tract Urothelial Carcinoma

Objectives: Urothelial carcinoma of the renal pelvis and ureter is a relatively uncommon malignancy. The majority of patients present at a stage in which disease has not penetrated through the muscularis (Tis–T2). These patients are generally treated with radical nephroureterectomy or with renal-sparing procedures in select patients, and overall the prognosis is favorable in this group. However...

Urothelial Carcinoma

1Department of Pathology, College of Medicine, National Cheng Kung University, No.1 University Road, Tainan City 701, Taiwan 2Leeds Institute for Molecular Medicine, Section of Experimental Oncology, Cancer Research UK Clinical Centre, St Jame’s University Hospital, Beckett Street, Leeds LS9 7TF, UK 3 Johns Hopkins Medical Institutions, The James Buchanan Brady Urological Institute, 600 N. Wolf...